Coya Therapeutics, Inc. 8-K

What Happened
Coya Therapeutics, Inc. held its Annual Meeting of Stockholders on June 25, 2026 (reported on Form 8‑K). Stockholders elected Secretary Wilbur Ross and Dieter Weinand as Class I directors for three‑year terms and ratified the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Vote totals: Secretary Wilbur Ross — For 9,168,496; Withheld 2,818,233; Broker non‑votes 4,585,732. Dieter Weinand — For 10,566,702; Withheld 1,420,027; Broker non‑votes 4,585,732. Auditor ratification — For 16,545,887; Against 22,661; Abstain 3,913.

Key Details

• Annual Meeting date: June 25, 2026 (Form 8‑K filed reporting results).
• Directors elected to three‑year terms: Wilbur Ross and Dieter Weinand.
• Director vote counts: Ross — 9,168,496 for / 2,818,233 withheld; Weinand — 10,566,702 for / 1,420,027 withheld.
• Auditor ratified: Weaver and Tidwell, L.L.P. — 16,545,887 for; 22,661 against; 3,913 abstain. Broker non‑votes on director elections: 4,585,732.

Why It Matters
The vote confirms the company’s board composition for the next three years and maintains continuity in governance. Ratifying Weaver and Tidwell as the independent auditor secures the firm responsible for auditing Coya’s financial statements for fiscal 2026, an item investors watch for audit continuity and reporting reliability. The presence of substantial broker non‑votes on the director elections (4,585,732) simply reflects shares held by brokers that were not voted on those matters.